Neurotech Appoints Beth Marsh as Chief Commercial Officer

CUMBERLAND, R.I.--(BUSINESS WIRE)--Neurotech Pharmaceuticals, Inc., a private biotech company focused on developing transformative therapies for chronic eye diseases, announced the appointment of Beth Marsh as Chief Commercial Officer, effective April 28, 2025. In this role, Beth will lead the commercial organization, including preparing for the U.S. launch of ENCELTOTM (revakinagene taroretcel-lwey), the first and only approved treatment for adults with idiopathic Macular Telangiectasia Type 2